Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

47.50
-0.0750-0.16%
Volume:7.85M
Turnover:374.49M
Market Cap:96.66B
PE:17.79
High:48.19
Open:47.71
Low:47.28
Close:47.57
Loading ...

Bristol-Myers Squibb Company (BMY): Among the High Growth Dividend Paying Stocks to Invest in

Insider Monkey
·
10 Apr

Bristol-Myers Squibb Reportedly Gets Dismissal of Pomalyst Monopoly Suit

MT Newswires Live
·
10 Apr

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

Zacks
·
10 Apr

BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo

Zacks
·
10 Apr

Healthcare Stocks Aren't a Shelter From the Tariff Storm -- Barrons.com

Dow Jones
·
10 Apr

Why drug stocks are no longer a safe haven from the stock market's turmoil

Dow Jones
·
09 Apr

FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients

Benzinga
·
09 Apr

Major Pharma Stocks Down Amid Tariff Turmoil

MT Newswires Live
·
09 Apr

Bristol Myers wins dismissal of proposed Pomalyst class action, Reuters reports

TIPRANKS
·
09 Apr

Shares of Drugmakers Down After Trump Threatens Tariffs on Sector

THOMSON REUTERS
·
09 Apr

Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb to $36 From $37, Keeps Underweight Rating

MT Newswires Live
·
09 Apr

Morgan Stanley Remains a Sell on Bristol-Myers Squibb (BMY)

TIPRANKS
·
09 Apr

BRIEF-US FDA Approves Opdivo (Nivolumab) Plus Yervoy (Ipilimumab)

Reuters
·
09 Apr

Bristol Myers Squibb Co. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
09 Apr

U.S. Food and Drug Administration Approves Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) as a Treatment for Patients With Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

THOMSON REUTERS
·
09 Apr

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

Business Wire
·
09 Apr

Bristol-Myers Lands FDA Approval for Combination Treatment of Colorectal Cancer

MT Newswires Live
·
09 Apr

BRIEF-FDA Approves Nivolumab With Ipilimumab For Unresectable Or Metastatic MSI-H Or dMMR Colorectal Cancer

Reuters
·
09 Apr

FDA approves nivolumab with ipilimumab for additional indication

TIPRANKS
·
09 Apr

FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic Msi-H or Dmmr Colorectal Cancer

THOMSON REUTERS
·
09 Apr